Aptar's activ-film™ technology selected to protect new sars rapid antigen test for covid-19 diagnosis

Crystal lake, ill.--(business wire)--aptargroup, inc. (nyse: atr), a global leader in drug delivery, consumer product dispensing and active packaging solutions, announced that its activ-film™ technology was selected to protect a new sars rapid antigen test for covid-19 that recently received emergency use authorization (eua) from the u.s. food and drug administration (fda). the quickvue® sars antigen test is a point-of-care rapid antigen test developed by quidel® corporation, a leading manufact
ATR Ratings Summary
ATR Quant Ranking